LB 1410
Alternative Names: LB-1410Latest Information Update: 25 Jun 2024
At a glance
- Originator L and L Biopharma
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; HAVCR2 protein inhibitors; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
- Phase I Lymphoma
Most Recent Events
- 21 Jun 2024 L and L Biopharma plans a phase I/II TRIGGERCD8 trial for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV) in June 2024(NCT06468358)
- 19 Jun 2024 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy) in China (IV) (NCT06468358)
- 31 May 2024 Adverse events, efficacy, pharmacokinetics and immunogenicity data from phase I trial in Lymphoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)